April 09, 2026

The molecular research “booster” evolves: SIMPLAIX collaboration starts the next phase

The molecular research “booster” evolves: SIMPLAIX collaboration starts the next phase

Computer simulations and Artificial Intelligence are the main pillars of the “SIMPLAIX” collaboration, initiated by the Heidelberg Institute for Theoretical Studies (HITS). Together with colleagues from Heidelberg University and Karlsruhe Institute of Technology (KIT), HITS researchers are addressing challenges in the simulation of biomolecules and molecular materials by pooling their expertise in multiscale computer simulation and machine learning. Established in 2021, SIMPLAIX has been successfully evaluated and has now started its second phase, with the Max Planck Institute for Polymer Research (MPIP) as an additional partner. The initiative is funded by the Klaus Tschira Foundation.

Molecular mechanisms and the rational design of molecules and materials for specific applications have traditionally been explored using physics-based modeling and simulations. These methods have revolutionized modern science and technology. However, they reach their limits when it comes to mapping, exploring, and analyzing the infinitely complex and variable structures and properties of molecular systems over the wide range of relevant scales. Here, data-driven and machine learning methods offer a promising approach.

This is why the Heidelberg Institute for Theoretical Studies (HITS), Heidelberg University, and the Karlsruhe Institute of Technology (KIT) launched the SIMPLAIX collaboration in 2021. They combine the expertise of the three partner institutions to address the challenges of bridging scales in simulating biomolecules and molecular materials through multiscale simulation and machine learning.
Along with collaborative research projects, the first years saw well-attended international workshops and many internal meetings, a remarkable number of publications and several awards for SIMPLAIX PIs, among them an ERC Advanced Grant and a DFG Heinz-Maier Leibnitz Prize.

After a successful evaluation, SIMPLAIX has started its second phase, gaining additional strength by the addition of a new associate partner: The Max Planck Institute for Polymer research (MPIP) in Mainz. With 10 principal investigators (PIs) and 8 projects, SIMPLAIX will evolve and broaden the cross-disciplinary and cross-institutional scientific collaborations in the research projects.

In addition, the highly successful SIMPLAIX workshop series will continue in May 2026. The registration is open: https://simplaix-workshop2026.h-its.org/.  This year’s workshop will be jointly organized with RTG 2450, a DFG-funded research graduate school at KIT.

SIMPLAIX is coordinated by HITS researcher Rebecca Wade, supported by HITS Alumna Frauke Gräter, now Director at the MPIP. The Klaus Tschira Foundation provides financial support which is complemented by the four participating institutions.

More information: www.simplaix.org

Scientific contact:
Prof. Dr. Rebecca Wade
Molecular and Cellular Modeling Group (MCM)
Heidelberg Institute for Theoretical Studies (HITS),

Press contact:
Angela Michel
Head of Communications
Heidelberg Institute for Theoretical Studies (HITS)
E-Mail: angela.michel@h-its.org
www.h-its.org

Our latest News

discover more
European Biotech Act: bioRN brings Industry and Policymakers together

European Biotech Act: bioRN brings Industry and Policymakers together

How can Europe strengthen its global competitiveness in biotechnology? Heidelberg, July 7th: This question was at the heart of a high-level roundtable hosted by the bioRN Life Science Cluster with Member of the European Parliament Hildegard Bentele. Representatives from Ascendis Pharma, BD, PROGEN, Novaliq, BASF Agricultural Solutions, PEPperPRINT, Evotec and Isenbruck Bösl Hörschler joined the […]

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp